礼来公司正在向FDA申请将欣百达适应症扩展到慢性疼痛，例如因关节炎导致的膝盖疼痛和腰疼。
Lilly is seeking FDA approval for Cymbalta as a treatment for chronic pain conditions such as knee pain caused by osteoarthritis and lower back pain.
礼来y公司的临床试验证明，有三分之二的病人在服用欣百达三个月后，腰疼得到缓解。
Two out of three studies Lilly conducted in patients with lower back pain showed the product improved pain relief over about a three-month period.
但是FDA还是会允许礼来公司将欣百达作为止痛药在市场上销售。
However, it would allow Lilly to market Cymbalta as a pain treatment.
应用推荐